BioCentury
ARTICLE | Company News

Biogen ups biosimilar JV stake

June 28, 2018 9:43 PM UTC

Biogen Inc. (NASDAQ:BIIB) exercised its option to increase ownership in Samsung Bioepis to about 49.9% from 5.4%. Samsung Bioepis is a biosimilars JV between Biogen and Samsung BioLogics Co. Ltd. (KSE:207940), which will receive $700 million from Biogen...